(Bloomberg) -- Eli Lilly & Co. agreed to buy U.S. biopharma company Morphic Holding Inc. for about $3.2 billion to gain experimental therapies for inflammatory bowel disease and other chronic illnesses. Most Read from Bloomberg Biden Narrows Gap With Trump in Swing States Despite Debate Loss Hedge Funds That Piled Into Big Tesla Short Stung by Rally Boeing to Plead Guilty to Fraud for Violating Deal Over 737 Max Crashes French Left Set for Shock Victory Over Macron and Le Pen Lilly will pay $57 a share for Waltham, Massachusetts-based Morphic, or 79% more than the closing price Friday, the companies said in a statement Monday. Morphic’s board recommends that stockholders tender their shares in the offer. Morphic is developing a so-called selective oral small molecule inhibitor for the treatment of inflammatory bowel disease. The experimental therapy is currently being evaluated in two mid-stage studies in ulcerative colitis, and an early-stage trial in Crohn’s disease. Most Read from Bloomberg Businessweek A World-First Psychedelics Experiment Is Unfolding in Australia How Stocks Became the Game That Record Numbers of Americans Are Playing Dragons and Sex Are Now a $610 Million Business Sweeping Publishing The Rich Investor Club Is Getting Crowded Online Shopping Warehouses Are Reshaping Rural America ©2024 Bloomberg L.P.
Lilly agrees to buy US biotech Morphic in $3.2 billion deal
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...